Profile data is unavailable for this security.
About the company
Boston Scientific Corporation is a global developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. Its MedSurg segment includes Endoscopy, Urology and Neuromodulation. Its Endoscopy business develops and manufactures devices to diagnose and treat a broad range of gastrointestinal (GI) and pulmonary conditions with less invasive technologies. Its Urology business develops and manufactures devices to treat various urological conditions for both male and female anatomies. Its Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. Its Cardiovascular segment includes Cardiology and Peripheral Interventions. Its Interventional Cardiology Therapies business develops and manufactures technologies for diagnosing and treating coronary artery disease and aortic valve conditions. It also owns the transcarotid artery revascularization (TCAR) platform.
- Revenue in USD (TTM)15.91bn
- Net income in USD1.79bn
- Incorporated1979
- Employees48.00k
- LocationBoston Scientific Corp300 Boston Scientific WayMARLBOROUGH 01752-1291United StatesUSA
- Phone+1 (508) 683-4000
- Fax+1 (508) 650-8923
- Websitehttps://www.bostonscientific.com/en-US/Home.html
Mergers & acquisitions
| Acquired company | BSX:NYQ since announced | Transaction value |
|---|---|---|
| Silk Road Medical Inc | 18.13% | 1.25bn |
| Axonics Inc | 54.75% | 3.67bn |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Medtronic PLC | 33.00bn | 4.29bn | 110.56bn | 95.00k | 26.30 | 2.28 | 15.88 | 3.35 | 3.28 | 3.28 | 25.19 | 37.81 | 0.3664 | 2.03 | 5.41 | 347,326.30 | 4.80 | 4.57 | 5.47 | 5.14 | 65.46 | 66.75 | 13.10 | 13.49 | 1.39 | 9.82 | 0.3677 | 80.58 | 3.64 | 1.16 | -2.18 | -4.56 | 6.95 | 6.65 |
| Boston Scientific Corporation | 15.91bn | 1.79bn | 132.64bn | 48.00k | 74.40 | 6.40 | 43.88 | 8.34 | 1.21 | 1.21 | 10.73 | 14.05 | 0.4412 | 1.91 | 6.91 | 331,458.30 | 4.96 | 2.50 | 5.85 | 2.91 | 69.09 | 68.84 | 11.24 | 6.47 | 1.02 | 6.02 | 0.3419 | 0.00 | 12.29 | 7.71 | 144.55 | -0.4276 | 7.82 | -- |
| Stryker Corp | 21.97bn | 3.59bn | 146.71bn | 52.00k | 41.25 | 7.28 | 31.71 | 6.68 | 9.33 | 9.33 | 57.08 | 52.86 | 0.5368 | 1.56 | 6.27 | 422,576.90 | 8.77 | 6.60 | 10.76 | 7.84 | 63.88 | 63.99 | 16.34 | 13.13 | 1.22 | -- | 0.4345 | 43.70 | 11.11 | 8.55 | 34.22 | 9.68 | 0.1047 | 10.16 |
| Danaher Corp | 23.74bn | 3.93bn | 170.34bn | 61.00k | 44.50 | 3.32 | 27.55 | 7.17 | 5.30 | 5.24 | 32.05 | 71.03 | 0.2821 | 3.39 | 6.11 | 389,213.10 | 4.67 | 5.93 | 5.19 | 6.56 | 59.26 | 58.79 | 16.57 | 19.11 | 1.01 | 21.31 | 0.2546 | 14.33 | -10.33 | 6.98 | -32.50 | 11.85 | 16.10 | 11.32 |
| Intuitive Surgical, Inc. | 7.87bn | 2.24bn | 195.14bn | 13.68k | 88.07 | 12.52 | 70.75 | 24.81 | 6.22 | 6.22 | 21.81 | 43.75 | 0.4848 | 1.98 | 7.44 | 575,234.00 | 13.93 | 12.42 | 15.63 | 13.83 | 66.98 | 67.60 | 28.73 | 26.31 | 3.42 | -- | 0.00 | 0.00 | 14.49 | 13.85 | 35.98 | 9.77 | 41.53 | -- |
| Thermo Fisher Scientific Inc | 42.37bn | 6.14bn | 196.32bn | 122.00k | 32.19 | 4.01 | 20.88 | 4.63 | 15.95 | 15.95 | 110.12 | 128.08 | 0.4292 | 4.63 | 4.32 | 347,295.10 | 6.28 | 7.79 | 7.36 | 9.11 | 40.77 | 44.94 | 14.62 | 16.76 | 1.26 | 24.08 | 0.4183 | 6.75 | -4.58 | 11.96 | -13.74 | 14.43 | 14.30 | 15.39 |
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 30 Sep 2024 | 124.78m | 8.47% |
| Fidelity Management & Research Co. LLCas of 30 Sep 2024 | 113.33m | 7.70% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 69.25m | 4.70% |
| SSgA Funds Management, Inc.as of 30 Sep 2024 | 62.85m | 4.27% |
| PRIMECAP Management Co.as of 30 Sep 2024 | 37.83m | 2.57% |
| Wellington Management Co. LLPas of 30 Sep 2024 | 30.86m | 2.10% |
| Geode Capital Management LLCas of 30 Sep 2024 | 29.58m | 2.01% |
| Massachusetts Financial Services Co.as of 30 Sep 2024 | 25.67m | 1.74% |
| BlackRock Investment Management (UK) Ltd.as of 30 Sep 2024 | 23.70m | 1.61% |
| Capital Research & Management Co. (World Investors)as of 30 Sep 2024 | 21.68m | 1.47% |
